New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients - Amarin Corp (NASDAQ:AMRN)

Amarin (AMRN) reported Q2 2026 results on an earnings call. Total net revenue was $42.2M, down 42% year over year, mainly due to a $25M upfront licensing payment in 2025. U.S. product revenue fell to $32.2M, while Europe product revenue rose to $5.4M. Operating loss narrowed to $12.0M and cash and investments were $314.6M.

Strong international demand growth and lower operating expenses supported improved profitability metrics as Amarin reaffirmed confidence in its global commercialization strategy. Key Investor Takeaways Amarin (NASDAQ:AMRN) reported strong international in-market demand growth, with partner network sales increasing 59% year over year despite lower reported revenue.

AMARIN CORP PLC\UK (AMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amrn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence Q2 2026 Results Highlight Global Volume Growth,

Amarin (NASDAQ: AMRN) reported Q2 2026 results for the quarter ended June 30, 2026. Total net revenue fell to $42.2 million from $72.7 million in Q2 2025, while operating expenses dropped 59% to $27.0 million. The company said in-market demand for VASCEPA/VAZKEPA rose 59% YoY across its partner network and U.S. IPE market share increased to 48%. It expects FY 2026 cash growth and continued international volume growth under its Recordati partnership.

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.